SOLICITATION NOTICE
B -- HIV-1 Drug Resistance Characterization - Genotypic and Phenotpic Analysis of HIV-1 Strains
- Notice Date
- 6/27/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, Center for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, GA, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2002-N-00451
- Response Due
- 8/12/2002
- Archive Date
- 8/27/2002
- Point of Contact
- Cheryl Stauss, Contract Specialist, Phone (770)488-2685, Fax (770)488-2670, - Cheryl Stauss, Contract Specialist, Phone (770)488-2685, Fax (770)488-2670,
- E-Mail Address
-
CStauss@CDC.GOV, CStauss@CDC.GOV
- Description
- The Centers for Disease Control and Prevention (CDC) intends to award a fixed price contract for laboratory studies on antiretroviral drug resistance and HIV subtypes for selected HIV-1 strains from throughout the United States. The majority of the specimens will be sera. Two methods shall be used by the contractor, the first, genotypic characterization, shall be used on all serum and plasma specimens and involves amplification by PCR methods and direct genetic sequencing of all the protease and the first 333 amino acids of the reverse transcriptase area of the HIV-1 virus. The second, phenotypic characterization of antiretroviral susceptibility to reverse transcriptase and protease inhibitors, shall be used on a subset of specimens, determined by the project officer, through a recombinant virus assay. The vendor shall use all of the protease and at least the first 333 amino acids of the RT region, using the same amplified material as for the genotypic analysis. The contractor shall possess the following minimum qualifications to perform these tasks: the contractor must be able to perform sequencing for genotypic analysis and conduct phenotypic analysis by an established recombinant virus assay or subcontract to have the phenotypic analysis performed. The contractor (or its subcontractor) shall have experience in providing specialized information through phenotypic drug susceptibility. The contractor must be capable of providing genotypic results to the Department of Health and CDC within 30 days of specimen receipt, and phenotypic results within 30 days of receipt of the request to perform phenotyping. The contractor must have published articles on antiretroviral drug resistance. The anticipated performance period is 36 months or when 4,610 specimens have been genotyped and, based on the genotypic results, when approximately 560 of those specimens have been phenotyped, whichever comes first. An option for the genotyping of up to 10,090 additional specimens, and the phenotyping of up to 1,150 specimens, may be exercised during this time period. The solicitation will be issued as a full and open competition procurement. The NAICS code for this procurement is 541710. See Numbered Note 26. Upon issuance, the RFP will be available on the Internet at www.eps.gov. The date specified for receipt of offers will be approximately 30 days after the solicitation issue date. The solicitation issue date will be on or about July 12, 2002.
- Record
- SN00100576-W 20020629/020627213127 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |